Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Kari J. Kurppa, Yao Liu, Ciric To, et al.
Cancer Cell (2020) Vol. 37, Iss. 1, pp. 104-122.e12
Open Access | Times Cited: 369

Showing 1-25 of 369 citing articles:

Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Anwesha Dey, Xaralabos Varelas, Kun‐Liang Guan
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 7, pp. 480-494
Open Access | Times Cited: 615
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng Fu, Minru Liao, Rui Qin, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 502
Rational combinations of targeted cancer therapies: background, advances and challenges
Haojie Jin, Liqin Wang, René Bernards
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 3, pp. 213-234
Closed Access | Times Cited: 253
Persistent Cancer Cells: The Deadly Survivors
Shensi Shen, Stéphan Vagner, Caroline Robert
Cell (2020) Vol. 183, Iss. 4, pp. 860-874
Open Access | Times Cited: 223
Emerging role of tumor cell plasticity in modifying therapeutic response
Siyuan Qin, Jingwen Jiang, Yi Lü, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 198
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Julia Boshuizen, Daniel S. Peeper
Molecular Cell (2020) Vol. 78, Iss. 6, pp. 1002-1018
Open Access | Times Cited: 155
The Hippo Pathway in Liver Homeostasis and Pathophysiology
Jordan H. Driskill, Duojia Pan
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 299-322
Open Access | Times Cited: 150
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Stefano Piccolo, Tito Panciera, Paolo Contessotto, et al.
Nature Cancer (2022)
Open Access | Times Cited: 148
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
Monique B. Nilsson, Huiying Sun, Jacqulyne Robichaux, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 559
Open Access | Times Cited: 145
Cell–matrix interface regulates dormancy in human colon cancer stem cells
Yuki Ohta, Masayuki Fujii, Sirirat Takahashi, et al.
Nature (2022) Vol. 608, Iss. 7924, pp. 784-794
Closed Access | Times Cited: 133
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Heidie Frisco Cabanos, Aaron N. Hata
Cancers (2021) Vol. 13, Iss. 11, pp. 2666-2666
Open Access | Times Cited: 132
Hippo signalling in the liver: role in development, regeneration and disease
Jacquelyn O. Russell, Fernando D. Camargo
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 5, pp. 297-312
Open Access | Times Cited: 131
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity
Joel D. Pearson, Katherine Huang, Marek Pacal, et al.
Cancer Cell (2021) Vol. 39, Iss. 8, pp. 1115-1134.e12
Open Access | Times Cited: 121
Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy
Masashi Mikubo, Yoshiaki Inoue, Geoffrey Liu, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 11, pp. 1798-1809
Open Access | Times Cited: 115
Insights into recent findings and clinical application of YAP and TAZ in cancer
James Franklin, ZhengMing Wu, Kun‐Liang Guan
Nature reviews. Cancer (2023) Vol. 23, Iss. 8, pp. 512-525
Closed Access | Times Cited: 113
Small extracellular vesicles in combination with sleep-related circRNA3503: A targeted therapeutic agent with injectable thermosensitive hydrogel to prevent osteoarthritis
Shi‐Cong Tao, Ji‐Yan Huang, Yuan Gao, et al.
Bioactive Materials (2021) Vol. 6, Iss. 12, pp. 4455-4469
Open Access | Times Cited: 107
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
Thijs J. Hagenbeek, Jason R. Zbieg, Marc Hafner, et al.
Nature Cancer (2023) Vol. 4, Iss. 6, pp. 812-828
Open Access | Times Cited: 96
Therapeutic targeting of TEAD transcription factors in cancer
Ajaybabu V. Pobbati, Ramesh Kumar, Brian P. Rubin, et al.
Trends in Biochemical Sciences (2023) Vol. 48, Iss. 5, pp. 450-462
Closed Access | Times Cited: 83
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter, et al.
Cancer Cell (2022) Vol. 40, Iss. 7, pp. 754-767.e6
Open Access | Times Cited: 81
Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells
Yang Sun, Lu Hu, Zhipeng Tao, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 78
Lung cancer in patients who have never smoked — an emerging disease
Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 121-146
Open Access | Times Cited: 75
Control of stem cell renewal and fate by YAP and TAZ
Jordan H. Driskill, Duojia Pan
Nature Reviews Molecular Cell Biology (2023) Vol. 24, Iss. 12, pp. 895-911
Closed Access | Times Cited: 72
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Yi Pu, Lu Li, Haoning Peng, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 799-813
Closed Access | Times Cited: 69
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Fernando J. de Miguel, Claudia Gentile, William W. Feng, et al.
Cancer Cell (2023) Vol. 41, Iss. 8, pp. 1516-1534.e9
Open Access | Times Cited: 53
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS
Yuta Adachi, Ryo Kimura, Kentaro Hirade, et al.
Nature Cancer (2023) Vol. 4, Iss. 6, pp. 829-843
Closed Access | Times Cited: 50
Page 1 - Next Page

Scroll to top